The burden of multimorbidity in patients with systemic lupus erythematosus - single-centre analysis.

IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Marketa Dudkova, Martina Skacelova, Pavel Horak, Jakub Videman, Adela Skoumalova
{"title":"The burden of multimorbidity in patients with systemic lupus erythematosus - single-centre analysis.","authors":"Marketa Dudkova, Martina Skacelova, Pavel Horak, Jakub Videman, Adela Skoumalova","doi":"10.5507/bp.2025.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Multimorbidity is a growing problem in the general population as well as in patients with rheumatic diseases like systemic lupus erythematosus (SLE). However, patients with SLE have twice the risk of developing multimorbidity than non-SLE patients. The aim of this study was to determine the prevalence of multimorbidity in patients with SLE treated in a university hospital.</p><p><strong>Methods: </strong>This was a cross-sectional single-centre study and included patients diagnosed and treated with SLE fulfilling the EULAR/ACR 2019 classification criteria. Multimorbidity was defined as the co-occurrence of at least two chronic diseases in an individual. The multimorbidity status was determined by a simple count of associated diseases, as well as using the Rheumatic Disease Comorbidity Index (RDCI) and the Multimorbidity Index (MMI).</p><p><strong>Results: </strong>A total of 122 patients with SLE were included in the study. Multimorbidity was found in 94% of the participants. The median comorbidity score, as measured by RDCI, was 1.5, while the MMI score was 4. The most prevalent comorbidities as measured by the RDCI were hypertension (37%), other cardiovascular disease (28%), pulmonary disease (18%) and depression (9%). No correlation was found for the RDCI and MMI scores and current disease activity as measured by the SLEDAI-2K scoring system. However, there was a marked increase in the multimorbidity indices with increasing patient age.</p><p><strong>Conclusion: </strong>This study confirmed the high prevalence of the serious and often overlooked issue of multimorbidity in SLE patients. The RDCI and MMI were used to quantify comorbidities, as indices validated for usage in autoimmune rheumatic diseases, especially SLE. Due to the cross-sectional design of the study, it was not possible to determine the frequency of multimorbidity prior to diagnosis and its evolution with disease duration and activity. Nevertheless, the high prevalence of multimorbidity in this cohort underscores the importance of this issue.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Papers-Olomouc","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5507/bp.2025.004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Multimorbidity is a growing problem in the general population as well as in patients with rheumatic diseases like systemic lupus erythematosus (SLE). However, patients with SLE have twice the risk of developing multimorbidity than non-SLE patients. The aim of this study was to determine the prevalence of multimorbidity in patients with SLE treated in a university hospital.

Methods: This was a cross-sectional single-centre study and included patients diagnosed and treated with SLE fulfilling the EULAR/ACR 2019 classification criteria. Multimorbidity was defined as the co-occurrence of at least two chronic diseases in an individual. The multimorbidity status was determined by a simple count of associated diseases, as well as using the Rheumatic Disease Comorbidity Index (RDCI) and the Multimorbidity Index (MMI).

Results: A total of 122 patients with SLE were included in the study. Multimorbidity was found in 94% of the participants. The median comorbidity score, as measured by RDCI, was 1.5, while the MMI score was 4. The most prevalent comorbidities as measured by the RDCI were hypertension (37%), other cardiovascular disease (28%), pulmonary disease (18%) and depression (9%). No correlation was found for the RDCI and MMI scores and current disease activity as measured by the SLEDAI-2K scoring system. However, there was a marked increase in the multimorbidity indices with increasing patient age.

Conclusion: This study confirmed the high prevalence of the serious and often overlooked issue of multimorbidity in SLE patients. The RDCI and MMI were used to quantify comorbidities, as indices validated for usage in autoimmune rheumatic diseases, especially SLE. Due to the cross-sectional design of the study, it was not possible to determine the frequency of multimorbidity prior to diagnosis and its evolution with disease duration and activity. Nevertheless, the high prevalence of multimorbidity in this cohort underscores the importance of this issue.

系统性红斑狼疮患者多重发病的负担-单中心分析。
目的:在普通人群以及风湿性疾病如系统性红斑狼疮(SLE)患者中,多重发病是一个日益严重的问题。然而,SLE患者发生多病的风险是非SLE患者的两倍。本研究的目的是确定在一所大学医院接受治疗的SLE患者的多病患病率。方法:这是一项横断面单中心研究,纳入了诊断和治疗符合EULAR/ACR 2019分类标准的SLE患者。多病被定义为至少两种慢性疾病在个体中同时发生。通过简单的相关疾病计数,以及使用风湿病共病指数(RDCI)和多病指数(MMI)来确定多病状态。结果:研究共纳入122例SLE患者。在94%的参与者中发现多重发病。根据RDCI测量,共病评分中位数为1.5,而MMI评分为4。根据RDCI测量,最常见的合并症是高血压(37%)、其他心血管疾病(28%)、肺部疾病(18%)和抑郁症(9%)。SLEDAI-2K评分系统测量的RDCI和MMI评分与当前疾病活动性没有相关性。然而,随着患者年龄的增加,多病指数明显增加。结论:本研究证实了SLE患者中严重且常被忽视的多病问题的高患病率。RDCI和MMI被用来量化合并症,作为自身免疫性风湿性疾病,特别是SLE的有效指标。由于研究的横断面设计,不可能在诊断前确定多病的频率及其随疾病持续时间和活动的演变。然而,该队列中多病的高患病率强调了该问题的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomedical Papers-Olomouc
Biomedical Papers-Olomouc MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
2.30
自引率
0.00%
发文量
74
审稿时长
6-12 weeks
期刊介绍: Biomedical Papers is a journal of Palacký University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Czech Republic. It includes reviews and original articles reporting on basic and clinical research in medicine. Biomedical Papers is published as one volume per year in four issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信